Tag Archives: *VMAT2 inhibitor? What’s that?*

*VMAT2 inhibitor? What’s that?* Valbenazine (Ingrezza) is a selective inhibitor of vesicular monoamine transporter 2 (VMAT 2). In April, 2017, it was approved by the FDA for the treatment of adults with tardive dyskinesia. It is the first medication ever to be FDA-approved for the treatment of tardive dyskinesia. What is VMAT 2? VMAT2 sounds […]